---
title: "HSBC Research Keeps PHARMARON  at Buy, Expects Strong CDMO Growth to Offset FX Pressure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292841357.md"
description: "HSBC Research maintains a Buy rating on Pharmaron, raising its target price to HKD30.8 from HKD28.2. The broker expects strong CDMO growth of over 25% in 2026, driven by project conversion and commercial production, which will offset FX pressure on laboratory services. While full-year gross margin forecasts were lowered slightly due to FX impacts, resilient demand supports continued revenue growth."
datetime: "2026-07-16T02:40:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292841357.md)
  - [en](https://longbridge.com/en/news/292841357.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292841357.md)
generator: "portal-rs"
---

# HSBC Research Keeps PHARMARON  at Buy, Expects Strong CDMO Growth to Offset FX Pressure

HSBC Global Investment Research issued a research report saying that PHARMARON (03759.HK) +0.320 (+1.279%) Short selling $36.63M; Ratio 4.936% 's positive profit alert for the interim period showed revenue growth of 16% to 19% YoY during the period, broadly in line with the broker's expectations. Net profit increased 4% to 10% YoY, slightly below expectations, mainly due to a greater-than-expected impact from foreign exchange factors on the gross margin of laboratory services.

The broker expects resilient demand and order execution in PHARMARON (03759.HK) +0.320 (+1.279%) Short selling $36.63M; Ratio 4.936% 's CDMO business to continue, with full-year 2026 revenue expected to grow 16.4%. It lowered its full-year gross margin forecast by about 0.8 ppts to 34.4% to reflect FX pressure. For the CDMO business, the broker expects full-year 2026 CDMO revenue growth of more than 25%, benefiting from strong project conversion, increased contribution from commercial production and healthy customer demand. Meanwhile, improved operating efficiency is expected to bring about gross margin expansion of around 1 ppt, partially offsetting the negative foreign exchange impact on laboratory services. The clinical services business is expected to record only low-single-digit revenue growth.

The broker raised its TP from HKD28.2 to HKD30.8 and maintained the Buy rating.(gc/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-15 16:25.)

### Related Stocks

- [300759.CN](https://longbridge.com/en/quote/300759.CN.md)
- [03759.HK](https://longbridge.com/en/quote/03759.HK.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)

## Related News & Research

- [Pharmaron Beijing Co., Ltd. Class H (17Q1) was downgraded to a Hold Rating at UBS](https://longbridge.com/en/news/296967052.md)
- [Pharmaron Beijing announces extraordinary general meeting, H share class meeting](https://longbridge.com/en/news/296918409.md)
- [Transcenta Holding announces extraordinary general meeting](https://longbridge.com/en/news/296833106.md)
- [Marex management urges proactive FX risk strategy as volatility rises](https://longbridge.com/en/news/297011192.md)
- [HSBC HOLDINGS Reportedly Buys At Least USD3B of Indian Govt Bonds Over Past Few Mths](https://longbridge.com/en/news/296873196.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**